首页> 美国卫生研究院文献>Nature Public Health Emergency Collection >Major reduction of rotavirus but not norovirus gastroenteritis in children seen in hospital after the introduction of RotaTeq vaccine into the National Immunization Programme in Finland
【2h】

Major reduction of rotavirus but not norovirus gastroenteritis in children seen in hospital after the introduction of RotaTeq vaccine into the National Immunization Programme in Finland

机译:在芬兰国家免疫计划中引入RotaTeq疫苗后在医院中发现的儿童轮状病毒(而非诺如病毒)的胃肠炎大幅度减少

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Universal rotavirus (RV) vaccination is expected to reduce hospitalizations for acute gastroenteritis (GE) of children by eliminating most of severe RVGE, but it does not have any effect on norovirus (NV), the second most common causative agent of GE in children. After the introduction of the RV vaccine into the National Immunization Programme (NIP) of Finland in 2009, we conducted a prospective 2-year survey of GE in children seen in Tampere University Hospital either as outpatients or inpatients and compared the results with a similar 2-year survey conducted prior to NIP in the years 2006–2008. Compared with the pre-NIP 2-year period, in 2009–2011, hospitalizations for RVGE were reduced by 76 % and outpatient clinic visits were reduced by 81 %. NVGE showed a slight decreasing trend and accounted for 34 % of all cases of GE seen in hospital in pursuance of RVGE having decreased to 26 % (down from 52 %). In cases admitted to the hospital ward, RV accounted for 28 % and NV accounted for 37 %.The impact of RV vaccination was reflected as a 57 % decrease in all hospital admissions and 62 % decrease in all outpatient clinic visits for GE of any cause. : RV vaccination in NIP has led to a major reduction of hospital admissions and clinic visits due to RVGE, but has had no effect on NVGE. After 2 years of NIP, NV has become the leading cause of acute GE in children seen in hospital.
机译:通用轮状病毒(RV)疫苗有望通过消除大部分严重的RVGE来减少儿童的急性肠胃炎(GE)的住院治疗,但它对儿童中第二大最常见的GE致病因子诺如病毒(NV)没有任何影响。在2009年将RV疫苗引入芬兰的国家免疫计划(NIP)之后,我们对坦佩雷大学医院门诊或住院患者中的儿童进行了为期2年的GE前瞻性调查,并将结果与​​类似的2在2006-2008年进行NIP之前进行的年度调查。与NIP之前的两年相比,2009-2011年RVGE的住院治疗减少了76%,门诊就诊次数减少了81%。 NVGE呈轻微下降趋势,占因RVGE而在医院中发现的所有GE病例的34%,从52%下降至26%。在住院病房中,RV占28%,NV占37%.RV疫苗接种的影响反映为所有原因的所有住院次数减少57%,所有门诊就诊次数减少62% 。 :由于RVGE,NIP中的RV疫苗接种已大大减少了住院人数和门诊次数,但对NVGE没有影响。经过2年的NIP,NV已成为住院儿童中急性GE的主要原因。

著录项

相似文献

  • 外文文献
  • 中文文献
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号